Orion Bags Another Big Pharma Partner With Merck & Co Prostate Cancer Deal
Raises Outlook After Pact For ODM-208
The Finnish group has concluded an extensive search to partner its first-in-class CYP11A1 inhibitor, banking an impressive $290m upfront fee for the Phase II drug which is being evaluated for metastatic castration-resistant prostate cancer.
You may also be interested in...
With pharma sales up 13% in Q3, questions mount about investments in its pipeline to diversify beyond Keytruda and keep the momentum going after its top seller faces biosimilars in 2028.
In this week's podcast version of Five Must-Know Things: setback for a COVID-19 candidate; Chinese biotechs move into mRNA; Sanofi’s strategic moves into hemophilia; Orion’s deal for its novel prostate cancer candidate; and Roche’s evolving approach to platform deals.
Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.